O'Sullivan Miriam, SVP and Chief HR Officer at Boston Scientific (BSX), has demonstrated a consistent pattern of selling company stock over the past two years, with no recorded purchases in the same period. According to SEC Form 4 filings, her transactions total $232,640 in sales, all involving BSX shares. The most recent sales occurred in February 2026, with three disposals totaling $61,280—$21,746 on February 16, $24,586 on February 14, and $14,946 on February 13. These followed earlier sales in February 2025, including a $31,196 transaction on February 17 and a $30,878 sale the previous day. The filings indicate these were primarily open-market sales (coded "F"), with no acquisitions or option exercises (coded "A" or "M") reported during this period.
Miriam’s trading activity is exclusively concentrated in BSX, with no diversification across other securities. The sales, while not part of a single large divestment, reflect a steady reduction in her holdings over time. The absence of any buy transactions suggests a one-way disposition of shares, though the reasons remain undisclosed in the filings. The dollar values of individual sales range from modest amounts like $3,183 in February 2025 to more substantial sums exceeding $30,000. This pattern aligns with executives periodically liquidating equity as part of compensation or portfolio management, though the data does not indicate whether these sales were pre-planned under Rule 10b5-1 trading plans.
AI-assisted summary